The Five Traps of Ignoring Kinetics

If you’ve ever trusted a Ki value without asking how it was measured, you’ve already stepped into the trap.

In drug discovery, equilibrium constants look tidy. But biology isn’t tidy. Onset and offset rates (not just “final numbers”) decide which drugs succeed in patients and which ones die in development.

Affinity snapshots alone won’t save your pipeline. Kinetics will.

This session gives you precisely that. By the end, you’ll know how to confirm true equilibria, detect hidden drug activities, and separate safe candidates from toxic ones long before clinic. No more blind spots, only decisions rooted in reality.

In this session, you'll gain:

✅ Tools to confirm true equilibrium and avoid potency errors from premature reads

✅ Methods to detect hidden mechanisms—mixtures, dual effects, or time-dependent inhibition—through curve shapes and kinetics

✅ A framework to classify antagonists and rank compounds by offset rate, using rapid calcium assays

Potency Is a Ratio of Rates

Two ligands compete for the same receptor. Which wins? Not just the one with higher affinity, but the one that gets there faster and leaves slower. Think of it like catching a train: two passengers have tickets (affinity), but only the one who sprints to the platform on time (fast onset) and stays seated (slow offset) actually gets the ride.

Ignore this, and you’ll misrank compounds. Respect it, and you’ll see why drugs with identical Ki values diverge in vivo.

This is the first trap: assuming equilibrium when you haven’t reached it. 

Curves that “look fine” may hide non-equilibrated systems. The fix? Use curve shapes as diagnostics: flattened, biphasic, or lagging responses aren’t noise. They’re telling you to wait.

When Equilibrium Lies

Sometimes, numbers don’t add up. You calculate an equilibrium value that requires a physically impossible onset rate. That’s your signal: kinetics are moving faster than your tools can measure. It’s like calculating a runner’s pace and realizing they’d have to break the sound barrier to make the numbers work. The math itself is your clue that something else is happening.

This is the second trap: trusting impossible math. If you ignore it, you risk false certainty. If you detect it, you gain texture that equilibrium constants alone can’t provide.

And this texture matters; kinetics have separated safe dopamine antagonists from those with extrapyramidal side effects.

Hidden Mixtures, Hidden Risks

Peptides degrade. Drugs carry dual mechanisms. At equilibrium, these effects cancel. But kinetics unmasks them.

Instead of clean monophasic curves, you’ll see biphasic signatures or sequential shifts—first cholinesterase inhibition, then receptor blockade.

This is the third trap: assuming one mechanism when two are in play. Catch it early, and you avoid wasting months chasing the wrong SAR.

The Hemi-Equilibrium Problem

Calcium assays look simple. But if your antagonist has a slow offset, you’ll see depressed maximal responses that equilibrium theory can’t explain.

This is the fourth trap: classifying antagonists as weak when they’re just slow.

Flip it around, and you’ve got a shortcut: use depression of max in calcium assays to rapidly rank offset rates, and predict in vivo coverage before you ever dose an animal.

Fractal Potency: The Illusion of Nothing, Then Everything

Measure too soon, and low concentrations look inert. Suddenly, at higher doses, you see an exaggerated ‘bang’ of effect. It’s like waiting for popcorn: at first, nothing happens, then suddenly the bag explodes with pops. But that’s timing, not a different kind of corn. That’s not pharmacology. That’s kinetics.

This is the fifth trap: misclassifying your antagonist because you didn’t wait.

The cure is simple: extend equilibration. Once you do, the irregular potency vanishes, and the true profile emerges.

What You’ll Walk Away With

By the end of this session, you won’t just “know about kinetics.” You’ll know how to use kinetics to sharpen decisions:

• Confirm whether your system has truly equilibrated

• Detect hidden activities before they waste resources

• Classify antagonists by offset rate without waiting on PK data

• Spot time-dependent inhibition that signals toxic liabilities

• Avoid being fooled by fractal potency artifacts

This isn’t academic nuance. It’s the difference between building a solid pipeline and chasing ghosts.

Kinetics in Drug Discovery: Your Edge

If you’re still treating potency as a static number, you’re missing half the story. Kinetics turns confusion into clarity, reveals risks earlier, and helps you rank compounds by the criteria that matter most in patients.

This isn’t just another lecture. It’s a shift in how expert drug hunters see pharmacology. And once you see it, you’ll never go back.

Unlock “Kinetics: Advanced Applications”

Only in Terry’s Corner

Why Terry’s Corner

Most pharmacology training stops at equilibrium values. But discovery doesn’t. The reality is dynamic—ligands arrive, depart, and interact in ways that standard assays often miss. That’s where Terry’s Corner changes the game.

Here, you’ll find:

• Weekly lectures that sharpen the tools you actually use in discovery

• A growing on-demand library of lessons you can revisit whenever you need them

• Exclusive access to the next AMA session

• Direct engagement opportunities through AMAs and topic suggestions

• Practical insights distilled from decades of pharmacology experience

Whether you’re validating assays, refining kinetic models, or deciding which leads to advance, Terry’s Corner gives you the frameworks to detect hidden liabilities and uncover real drug potential.

See beyond the equilibrium. Make decisions with confidence.

🟢 40 years of expertise at your fingertips: Explore the complete library ➤

✳️ Want to know what’s inside? Read the latest articles ➤

Stay sharp between lectures. Subscribe to The Kenakin Brief today ➤